Filter Results:
(1,244)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- May 1987
- Teaching Note
Eli Lilly and Co. (A) and (B), Teaching Note
By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (A): Strategic Challenges
By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
Yoshino, Michael Y., and Thomas W. Malnight. "Eli Lilly, 1998 (A): Strategic Challenges." Harvard Business School Case 399-173, June 1999. (Revised October 1999.)
- June 1998
- Supplement
MBA Integrative Exercise: Competition & Strategy, April 1998 , Video
By: Carin-Isabel Knoop
Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details
Knoop, Carin-Isabel. "MBA Integrative Exercise: Competition & Strategy, April 1998 , Video." Harvard Business School Video Supplement 898-504, June 1998.
- March 1993
- Supplement
Burroughs Wellcome and AZT (C)
Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details
Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States
Emmons, Willis M., III. "Burroughs Wellcome and AZT (C)." Harvard Business School Supplement 793-115, March 1993.
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
- March 1997
- Teaching Note
Eli Lilly and Company: Innovation in Diabetes Care TN
By: Clayton M. Christensen and Bret J. Baird
Teaching Note for (9-696-077). View Details
Keywords: Pharmaceutical Industry
- December 1998 (Revised September 1999)
- Case
Novartis: Betting on Life Sciences
By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder
The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details
Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Srinivas Sunder. "Novartis: Betting on Life Sciences." Harvard Business School Case 599-076, December 1998. (Revised September 1999.)
- January–February 1994
- Article
Financial Engineering at Merck
By: Timothy A. Luehrman
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
- November 18 2004
- Article
Merck's Recall of Rofecoxib: A Strategic Perspective
By: Felix Oberholzer-Gee and Noorein Inamdar
Oberholzer-Gee, Felix, and Noorein Inamdar. "Merck's Recall of Rofecoxib: A Strategic Perspective." New England Journal of Medicine 351, no. 21 (November 18 2004): 2147–2149.
- April 1999 (Revised May 2000)
- Case
Pilgrim Drug Company
David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
- February 26, 2003
- Article
Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising
By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman
Weissman, Joel S., David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman, and Robert Leitman. "Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising." Health Affairs (February 26, 2003).
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 11 May 2020
- Op-Ed
Immigration Policies Threaten American Competitiveness
It is no secret that immigration has reshaped American innovation. Immigrants are the backbone of America’s most innovative industries, provide a quarter of our patent applications, and are numerous among our science and engineering superstars. Taken from World... View Details
Keywords: by William R. Kerr
Arjun Goyal
on the boards of Scorpion Therapeutics, Quanta Therapeutics, Alterome Therapeutics, Halda Therapeutics, Third Arc Bio, and Centessa Pharmaceuticals (NASDAQ: CNTA) and as a co-founder and director, Affini-T Therapeutics. Furthermore, he... View Details
Keywords: Finance
Arjun Goyal
a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr... View Details
- Profile
Rocio Parra
Why was getting a business education important to you? As a consultant, I had the opportunity to work in a variety of industries from pharmaceuticals and medical devices to government and consumer packaged goods. Through these... View Details
Keywords: Retail
- Portrait Project
Mickey Millar
roach. Each incident left a stain on my spirit. While studying social welfare at HKS, I worked part-time so my pregnant sister wouldn't become homeless after she lost her job while on bed rest. During pharmaceutical case discussions at... View Details
- Fast Answer
Patent search: Product-associated patents
face="Open Sans"> Check company website. Some companies may lists patents associated with their products on their websites. For View Details
Steve Cagnetta
pharmaceutical and medical device companies. From time to time, he has represented and advised venture and angel groups on various matters. Prior to founding Company Counsel, Steve practiced at Hutchins, Wheeler & Dittmar, in Boston and... View Details